A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

NCT00723411 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

334

Enrollment

INDUSTRY

Sponsor class

Stopped The primary endpoint at 15 months was not met.

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: rhGAD65
DRUG: rhGAD65
DRUG: Placebo

Sponsor

Diamyd Therapeutics AB